PAT and continuous control gain pharma support; open control doesn’t

June 5, 2006

Pharmaceutical Manufacturing just published results of its first survey on the use of process control in the pharmaceutical industry. Among the findings:

  • A growing number of companies are launching process analytical technologies(PAT) initiatives
  • There's growing receptiveness to the concept of continuous processing, and advanced process control, within the industry.
  • Drug manufacturers are either ignorant of, or somewhat hostile, to the concepts of open control advanced by the ISA/ANSI standards 95 and 88, which several other industries have adopted.

For more insights, here's a summary of the survey results. We'll be expanding this survey and circulating it to more folks in the industry in the future, and would appreciate any of your suggestions/constructive criticism.

-AMS

Pharmaceutical Manufacturing just published results of its first survey on the use of process control in the pharmaceutical industry. Among the findings:

  • A growing number of companies are launching process analytical technologies(PAT) initiatives
  • There's growing receptiveness to the concept of continuous processing, and advanced process control, within the industry.
  • Drug manufacturers are either ignorant of, or somewhat hostile, to the concepts of open control advanced by the ISA/ANSI standards 95 and 88, which several other industries have adopted.

For more insights, here's a summary of the survey results. We'll be expanding this survey and circulating it to more folks in the industry in the future, and would appreciate any of your suggestions/constructive criticism.

-AMS

About the Author

pharmamanufacturing | pharmamanufacturing